More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$7.47B
EPS
1.31
P/E ratio
82.2
Price to sales
7.4
Dividend yield
--
Beta
0.071389
Previous close
$94.23
Today's open
$94.23
Day's range
$93.29 - $95.70
52 week range
$37.02 - $99.31
show more
CEO
Sanj K. Patel
Employees
366
Headquarters
London,
Exchange
Nasdaq Global Select
Shares outstanding
78571705
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
LONDON, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 11:00 a.m. Greenwich Mean Time (6:00 a.m. Eastern Time).
GlobeNewsWire • Nov 11, 2026

Here's Why Kiniksa Pharmaceuticals International, plc (KNSA) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research • Nov 4, 2026

Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Kiniksa raised 2026 revenue guidance to over $1.045 billion. ARCALYST penetration among multiple recurrence patients reached 23%.
The Motley Fool • Oct 27, 2026

What Kiniksa Pharmaceuticals International (KNSA) Said on Its Q3 Earnings Call
Kiniksa Pharmaceuticals International NASDAQ: KNSA raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the drug for recurrent pericarditis and advance its clinical pipeline.
MarketBeat • Oct 27, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 27, 2026

Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal Phase 3 data expected in 2H 2027 – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported third quarter 2026 financial results and recent portfolio execution. “Kiniksa continues to build a leading IL-1α and IL-1β inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis.
GlobeNewsWire • Oct 27, 2026

Kiniksa Pharmaceuticals International, plc (KNSA) Q3 Earnings and Revenues Surpass Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.23 per share a year ago.
Zacks Investment Research • Oct 27, 2026

Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
LONDON, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 27, 2026 at 8:30 a.m. Eastern Time to report its third quarter 2026 financial results and recent portfolio execution.
GlobeNewsWire • Oct 22, 2026

Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why
KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
Zacks Investment Research • Sep 17, 2026

Biopharmaceutical Leader Kiniksa Poised To Hit New Buy Point After Big Revenue Beat
Biotech leader Kiniksa stock is poised to hit a fresh buy point after shares soared 25% in response to better-than-expected sales numbers.
Investors Business Daily • Sep 10, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Kiniksa Pharmaceuticals International plc commission-free¹. Build wealth for the long term using automated trading and transfers.